PM mOOvers 👀 $DARE -Bayer And Daré Bioscience Announce Exclusive Licensing Agreement For US Commercial Rights To Ovaprene, An Investigational Hormone-Free, Monthly Contraceptive; Daré To Receive Upfront Payment Of $20M And Up To $310M In Milestones $ADAP -Adaptimmune Announces that SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications $BYND - China's Beyond Meat Competitor Seeks $2M Funding, Eyes Local Meatless Market Ahead Of US Rivals $OBSV -ObsEva and Yuyuan BioScience Technology Announce Sublicense Agreement to Develop and Commercialize Nolasiban in the People's Republic of China
  • 1